Chinese life science company HitGen has raised CNY250m ($39.1m) in a series B financing round from CDH Investments and Leadyond Capital.
HitGen plans to use the proceeds for expanding research and development activities and strengthening its drug discovery technology platform.
Singapore-based clinical-stage biotech company Lion TCR has raised $20m in a series A financing round from undisclosed existing investors, and new investors such as Yashang Capital and Westlake Ventures Capital.
Lion TCR plans to use the proceeds to finance the ongoing clinical trials of its lead candidate LioCyx in China and Singapore. Part of the funds will also be used for the expansion of its product pipeline.
Information Medical (MICIN) has secured ¥1.1bn ($10.05m) in a series A funding round led by Mitsubishi Corporation and others.
Based in Japan, MICIN is a Curon mobile telemedicine app and medical data business provider, while Mitsubishi Corporation is a trading company also based in Japan.
US-based biotherapeutic company Vital Therapies plans to issue 2.5 million shares in a public offering.
The company simultaneously plans to issue securities in a public offering to raise $200m.
Wilson Sonsini Goodrich & Rosati has been appointed as legal adviser for the transaction.
US-based clinical-stage biotechnology company Avrobio has filed a registration statement with the US Securities and Exchange Commission (SEC) for an initial public offering (IPO) of shares to raise $86.25m.
The underwriters will have a 30-day option to buy additional shares.
Avrobio plans to use the proceeds for the development of its lead product candidate AVR-RD-01, as well as other product candidates. Part of the funds will also be used for research and development, as well as general and administrative expenses.
The company has appointed Morgan Stanley & Co., Cowen and Company, Wells Fargo Securities and Wedbush Securities as underwriters for the transaction.
US-based immunotherapies and vaccines developer Inovio Pharmaceuticals plans to issue securities to raise $250m.
The company plans to use the proceeds towards working capital needs, capital expenditure and other general corporate purposes.
Cooley has been appointed as legal adviser for the transaction.
Biopharmaceutical company JHL Biotech has raised $106m in debt financing from private equity firm VMS Investment Group.
Existing shareholders, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank also participated in the financing round.
JHL Biotech plans to use the funds towards the developments of its biosimilar treatments pipeline.
Ion Pacific was appointed as financial adviser for the transaction.